USFDA concludes inspection of NATCO’s Pharma Division, Kothur
The company received seven observations in the Form-483
The company received seven observations in the Form-483
QuantumNexis will serve as the innovative engine for HCTI's recurring revenue business lines
The company received one observation in the Form-483
The inspection concluded successfully, with the facility found to be in compliance with the required regulations
Sun Pharma gets 8 observations from USFDA for Halol facility
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
Subscribe To Our Newsletter & Stay Updated